[go: up one dir, main page]

WO1997000089A1 - Procede de detection et de localisation par radioisotope d'une inflammation chez un patient - Google Patents

Procede de detection et de localisation par radioisotope d'une inflammation chez un patient Download PDF

Info

Publication number
WO1997000089A1
WO1997000089A1 PCT/US1996/010452 US9610452W WO9700089A1 WO 1997000089 A1 WO1997000089 A1 WO 1997000089A1 US 9610452 W US9610452 W US 9610452W WO 9700089 A1 WO9700089 A1 WO 9700089A1
Authority
WO
WIPO (PCT)
Prior art keywords
iodine
bromine
oxygen
inflammation
radiopharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1996/010452
Other languages
English (en)
Inventor
Amin I. Kassis
S. James Adelstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of WO1997000089A1 publication Critical patent/WO1997000089A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers

Definitions

  • the invention relates to methods for detection of sterile inflammation as well as inflammation associated with a bacterial infection in a host.
  • Any inflammatory lesions present in the host are detected by a nuclear imaging technigue appropriate to the radioisotope present in the radiopharmaceutical agent: e.g., using a gamma camera, positron emission tomography, positron emission spectography, single photon emission computed tomography, or other suitable detection means.
  • a nuclear imaging technigue appropriate to the radioisotope present in the radiopharmaceutical agent: e.g., using a gamma camera, positron emission tomography, positron emission spectography, single photon emission computed tomography, or other suitable detection means.
  • the method of the invention involves the steps of (a) identifying a mammal (e.g., a human, non-human primate, cow, horse, pig, sheep, goat, rabbit, mouse, rat, guinea pig, hamster, cat, or dog) suspected of having an inflammation; (b) providing the mammal with a diagnostically effective dosage of a radiopharmaceutical consisting of a deoxyribonucleoside or deoxyribonucleotide labeled with a radioisotope of iodine, bromine, carbon, nitrogen, or oxygen; and (c) detecting an accumulation of radioactivity in a site in the mammal, the accumulation being an indication that the inflammation is present in the site.
  • a mammal e.g., a human, non-human primate, cow, horse, pig, sheep, goat, rabbit, mouse, rat, guinea pig, hamster, cat, or dog
  • a radiopharmaceutical consisting of a
  • Gamma emitting radioisotopes preferred for use in the method of the invention include iodine-123, iodine- 125, iodine-131, bromine-80m, and bromine-82.
  • Useful positron emitters include halogens such as bromine-75, bromine-76, bromine-77, bromine-80, iodine-122, iodine- 124, and iodine-126, as well as non-halogens such as carbon-11, nitrogen-13, oxygen-14 and oxygen-15.
  • the radioisotope is covalently attached to or synthesized as an integral part of a deoxyribonucleoside or deoxyribonucleotide.
  • Either purines or pyrimidines can be used.
  • deoxyribonucleosides are IUdR, BUdR, AdR, CdR, GdR, and TdR (i.e., iodo-uridine, bro o- uridine, adenosine, cytidine, guanidine, and thymidine deoxyribonucleosides, respectively).
  • deoxyribonucleotides such as the 5' mono-, di-, and triphosphate derivatives of each of the above deoxyribonucleosides.
  • the radiopharmaceutical agent of the invention is preferably provided in the form of a pharmaceutical composition which includes a diagnostically effective dosage of the agent in a pharmaceutically acceptable carrier suitable for injection into a mammal. It may be supplied in a kit for use in detecting and localizing inflammation in a host, which kit includes (a) a sterile vial containing the radiopharmaceutical agent optionally in a pharmaceutically acceptable carrier; (b) instructions for using the kit; and (c) optionally, a means (such as a syringe) for administering the radiopharmaceutical agent to the host.
  • the dosage is typically between about 0.5 millicuries (mCi) and about 500 mCi; for positron emitters, the preferred dosage is between about 0.5 mCi and about 30 mCi.
  • mCi millicuries
  • positron emitters the preferred dosage is between about 0.5 mCi and about 30 mCi.
  • FIGURE 1 is a bar graph showing the biodistribution of gallium-67 citrate after intravenous injection into rats after induction of a bacterial infection in the left hind leg muscle.
  • Biodistribution i ⁇ measured as a function of the percentage of the injected dose of radioisotope/gram of biopsy sample weight.
  • the white bars indicate distribution at 3 hours, while the cross-hatched bars indicate distribution at 24 hours, "n” indicates the number of animals tested.
  • T/B indicates the ratio of radioactivity detected in target (inflamed) tissues to radioactivity detected in background tissue.
  • FIGURE 2 is a bar graph showing the biodistribution of 125 I labeled deoxyuridine after intravenous injection into rats after induction of a bacterial infection in the left hind leg muscle. Biodistribution is measured as a function of the percentage of the injected dose of radioisotope/gram of biopsy sample weight. The white bars indicate distribution at 1 hour, the solid bars indicate distribution at 3 hours and the cross-hatched bars indicate distribution at 24 hours, "n” indicates the number of animals tested. "T/B” indicates the ratio of radioactivity detected in target (inflamed) tissues to radioactivity detected in background tissue.
  • FIGURE 3 is a bar graph showing the biodistribution of gallium-67 citrate after intravenous injection into rats after induction of sterile inflammation in the left hind leg muscle. Biodistribution is measured as a function of the percentage of the injected dose of radioisotope/gram of biopsy sample weight. The white bars indicate distribution at 3 hours and the cross-hatched bars indicate distribution at 24 hours, "n” indicates the number of animals tested. "T/B” indicates the ratio of radioactivity detected in target (inflamed) tissues to radioactivity detected in background tissue.
  • FIGURE 4 is a bar graph showing the biodistribution of 125 I labeled deoxyuridine after intravenous injection into rats after induction of sterile inflammation in the left hind leg muscle. Biodistribution is measured as a function of the percentage of the injected dose of radioisotope/gram of biopsy sample weight. The white bars indicate distribution at 1 hour, the solid bars indicate distribution at 3 hours, and the cross-hatched bars indicate distribution at 24 hours, "n” indicates the number of animals tested. "T/B” indicates the ratio of radioactivity detected in target (inflamed) tissues to radioactivity detected in background tissue.
  • FIGURES 5A-5C are scintigraphic images obtained from the animal model described with respect to FIGURE 1 at 1 (FIGURE 5A) , 3 (FIGURE 5B) and 24 (FIGURE 5C) hours after intravenous injection of gallium-67 citrate.
  • FIGURES 6A-6C are scintigraphic images obtained from the animal model described with respect to FIGURE 2 at 1 (FIGURE 6A) , 3 (FIGURE 6B) and 24 (FIGURE 6C) hours after intravenous injection of the radiopharmaceutical.
  • 123 I-labeled deoxyuridine was used as the radiopharmaceutical agent, instead of 125 I-labeled deoxyuridine.
  • FIGURES 7A-7C are scintigraphic images obtained from the animal model described with respect to FIGURE 3 at 1 (FIGURE 7A) , 3 (FIGURE 7B) and 24 (FIGURE 7C) hours after intravenous injection of the gallium-67 citrate.
  • FIGURES 8A-8C are scintigraphic images obtained from the animal model described with respect to FIGURE 4 at 1 (FIGURE 8A) , 3 (FIGURE 8B) and 24 (FIGURE 8C) hours after intravenous injection of the radiopharmaceutical.
  • 123 I-labeled deoxyuridine was used as the radiopharmaceutical agent of the experiment instead of 12s I-labeled deoxyuridine.
  • radiopharmaceutical agents of the invention are deoxyribonucleosides or their corresponding deoxyribonucleotides labeled with a radioisotope of iodine, bromine, carbon, nitrogen, or oxygen.
  • the labeling is accomplished without use of an intermediate linking molecule, such as the intermediate functional groups which often are used to bind radioisotopes of metallic ions to, for example, immuno ⁇ globulins: e.g., bifunctional chelating agents such as diethylenetriaminepentacetic acid (DTPA) and ethylenediaminetetraacetic acid (EDTA) .
  • DTPA diethylenetriaminepentacetic acid
  • EDTA ethylenediaminetetraacetic acid
  • Nucleosides useful in the invention include IUdR, BUdR, TdR, CdR, AdR, and GdR. Such nucleosides, and their corresponding 5'mono-, di-, and triphosphophate derivatives, may be purchased from commercial sources or synthesized by well-known techniques, as described, for example, in Bergstrom, et al . , J.Carbohyd. , " Nucleosides and Nucleotides” , 4:257-269, 1977, the disclosure of which is incorporated herein to illustrate knowledge in the art concerning synthesis of nucleosides and nucleotides.
  • any of the deoxynucleosides or deoxynucleotides used in the claimed method can be labelled in one or more sites with an isotope of carbon, nitrogen, or oxygen (e.g., carbon-11, nitrogen-13, oxygen-14, or oxygen-15) .
  • Certain of the deoxynucleosides and deoxynucleotides alternatively can be labelled with an isotope of a halogen.
  • IUdR (or the corresponding nucleotide) can be labelled with any isotope of iodine (e.g., iodine-122, iodine-123, iodine-124, iodine-125, iodine-126, or iodine-131)
  • BUdR (or the corresponding nucleotide) can be labelled with any isotope of bromine (e.g., bromine-75, bromine- 76, bromine-77, bromine-80, bromine-80m, or bromine-82) .
  • the rate and extent of localization in inflammatory lesions of both the radiopharmaceutical agents of the invention and gallium-67 citrate was tested in animal models of sterile and bacterial inflammation.
  • the labeled nucleo-sides and nucleotides of the invention were determined to be superior to the commonly used gallium-67 agent for obtaining rapid images of both infectious and ⁇ terile inflammatory lesion ⁇ .
  • a radioisotope for use as a label for in vivo diagnostic imaging the type of detection instrument available mu ⁇ t be considered.
  • the radioi ⁇ otope cho ⁇ en must have a type of decay which is detectable by a given type of instrument.
  • Still another important factor in ⁇ electing a radioactive label for in vivo diagnosis is that the half-life of the molecule must be long enough so that it is still detectable at the time of maximum uptake by the target, but short enough so that deleterious radiation with respect to the host i ⁇ minimized.
  • a radioi ⁇ otope used for in vivo imaging will produce a large number of photons in the 140-250 keV range, which may be readily detected by conventional nuclear imaging cameras.
  • radioisotopes used to label the nucleosides or nucleotides of the invention will preferably be those which will not interfere with cellular incorporation of the nucleosides or nucleotides and which will retain the capacity for detectable decay despite such incorporation.
  • Types of radioisotopes which meet the aforementioned criteria for use in the method of the invention are those which emit gamma or positron radiation (hereafter, "gamma emitters” and “positron emitters” ) .
  • radioiodinated pyrimidine nucleosides and nucleotides are prepared by contacting a water-soluble halomercuri- pyri idine nucleoside or nucleotide with an aqueous medium containing a dis ⁇ olved radioactive iodide ion and an oxidizing agent.
  • the molar concentration of nucleoside or nucleotide in the reaction proces ⁇ exceeds that of the iodide.
  • the radioiodinated product of the reaction is separated from re ⁇ idual halomercuri- pyrimidine by conventional filtration procedures. The technique is useful in preparing any nucleoside or nucleotide labeled with a radioactive halogen.
  • radiopharmaceutical agents for use in the inventive method.
  • suitable radioiodination labeling techniques are taught in Keough et al . , J. Labeled Compound Radiopharm. 14:83-90, 1978.
  • Techniques for labeling with non-halogen radioisotopes are also well-known and include the technique referred to in Kubota et al . , Jpn . J. Cancer Res . 80:778-782, 1989.
  • the radiopharmaceutical agents will preferably be formulated in a pharmaceutically acceptable carrier, most preferably a liquid ( ⁇ ee. ⁇ tandard reference Remington' ⁇ Pharmaceutical Sciences, which is incorporated herein by reference to illustrate knowledge in the art concerning suitable pharmaceutical carriers) .
  • a pharmaceutically acceptable carrier most preferably a liquid
  • Exemplary liquid carriers are saline, Ringer' s ⁇ olution, syrup, peanut oil, olive oil and like emulsions.
  • the formulation can be in the form of an aqueous or nonaqueous liquid suspension and may include pharmaceutically acceptable preservatives.
  • the materials for use in the method of the invention are ideally suited for the preparation of a diagnostic kit.
  • Kits useful in the claimed method comprise container mean ⁇ ( ⁇ uch a ⁇ vials, tubes, bottles, and the like) as well as means (such a ⁇ a sterile ⁇ yringe) for admini ⁇ tering the content ⁇ of the container to a ho ⁇ t.
  • the ⁇ yringe may be provided already loaded with a single dose of the radiopharmaceutical agent, or the agent and/or a pharmaceutically acceptable carrier may be provided mixed or separated in one or more containers.
  • Appropriate instructions regarding the safe u ⁇ e of the radiopharmaceutical agent ⁇ of the invention will be provided on the container label ⁇ or in a separate instruction sheet.
  • the radiopharmaceutical agents of the invention may be used to detect and localize both sterile and bacterial inflammations.
  • the method of the invention is particularly advantageous in that it permits detection of acute inflammations and provide ⁇ diagno ⁇ tic re ⁇ ult ⁇ within 1 to 2 hour ⁇ of the administration of the radiopharmaceutical agent to the host.
  • the radiopharmaceutical agents of the invention can be expected to provide diagnostically sufficient images of inflammation for several hours, thus permitting detection of inflammation during the course of treatment.
  • SPECT single photon emission computed tomography
  • PET positron emis ⁇ ion tomography
  • Factor ⁇ to be considered in this re ⁇ pect include the exi ⁇ tence of any host sensitivity to a particular radioisotope, in vivo toxicity and efficiency of ⁇ uch molecule ⁇ , potential pharmaceutical interactions between the radiopharmaceutical agent and other medications taken by the host, the availability of particular detection instruments, and cost of materials.
  • the radiopharmaceutical agent is administered to the host in a dose which is diagnostically effective for the purpose.
  • diagnosis ⁇ tically effective mean ⁇ that the radiopharmaceutical agent i ⁇ administered in sufficient quantity to enable detection of any significant inflammatory lesion ⁇ pre ⁇ ent in the ho ⁇ t.
  • concentration of radiopharmaceutical agent to be administered should be cho ⁇ en such that its accumulation in inflammatory lesion ⁇ i ⁇ detectable compared to the background. Further, it i ⁇ desirable that the radiopharmaceutical agent be rapidly cleared from the circulatory system in order to give the best target-to- background signal ratio.
  • radiopharmaceutical agents display a preference for accumulation at inflammatory lesions in vivo. It has been hypothesized that phagocytosis plays a role or that the agent ⁇ accumulate in the extracellular spaces of tissues as a result of increased permeability of veins at the site of inflammation. Also, although the invention is not limited by any particular theory regarding why nucleosides and nucleotides will target inflammatory lesions in vivo, it is likely that they are incorporated into the nuclei of proliferating cells, such as bacteria at the site of an infection.
  • radiopharmaceutical agent ⁇ ufficient to concentrate in target ti ⁇ ue ⁇
  • the dosage of radiopharmaceutical agent required to detect inflammation in a host will vary with the radioactivity of the radioisotope present in the agent.
  • the mean lethal dosages of both 125 I and 123 I have been calculated at about 79 +/- 9 cGy (in Chinese hamster ovary cells; see, e.g., Makrigiorgos et al . ,
  • the dosage will of course be sub ⁇ tantially less than the mean lethal do ⁇ e for the radio-isotope. Because of the nature of gamma and positron emissions, the dosages of gamma emitters required by the invention will be les ⁇ than the dosages of positron emitters required by the invention.
  • the half-life of the radioisotope will also be taken into account, with a shorter half life meaning that a larger dose of radioactivity can be admini ⁇ tered safely. For example, the half-life of 123 I i ⁇ about 13 hours, while that of 131 I is about 8 days and that of 1X C is only 20 minutes.
  • a useful dose of the radiopharmaceutical would deliver between about 0.5 and about 500 millicuries (mCi) .
  • the radiopharmaceutical is a positron- emitter
  • the diagnositically effective dosage would be approximately 0.5 mCi to 30 mCi.
  • a u ⁇ eful do ⁇ e of 123 I-labelled deoxyribonucleoside or deoxyribonucleotide would be between 1 and 20 mCi, while les ⁇ than 5 mCi of the longer-lived 131 I would be u ⁇ ed (e.g. 0.5-5 mCi) .
  • Approximately 200 mCi 11 C can be u ⁇ ed (e.g., 100-300 mCi) .
  • the ⁇ e dosage ranges will not vary sub ⁇ tantially with the weight, age and sex of the host. However, in juvenile hosts, dosages in the lower ⁇ pectrum of each preferred dosage range will be preferred, in order to limit accumulation of radioactivity in dividing cells.
  • the radiopharmaceutical agents of the invention will be administered by a parenteral route selected to target the suspected site of inflammation.
  • the preferred route of administration will be by intravenous injection.
  • intra-arterial, intrathecal, and intraperitoneal routes may also be preferred for targeted acces ⁇ to certain organ ⁇ , such as the heart.
  • the site of inflammation may be imaged according to the invention more than once. Clearance of any previously administered radioactive agents (including those of the invention and chemotherapeutic agents) should be considered to limit detection of residual radioactivity. Rates of clearance may be determined based on known clearance rates for the particular radioisotopes present, or may be inferred by reimaging the host prior to read inistering a radiophar- maceutical agent according to the invention.
  • Radiopharmaceutical agent ⁇ of the invention Ac ⁇ cumulation of the radiopharmaceutical agent ⁇ of the invention in background will al ⁇ o be taken into account in thi ⁇ regard to maximize the target-to-background radioactivity ratios achieved in each imaging se ⁇ ion. Protocols and formulas for use in determining target-to-background ratios for radioactivity are well- known in the art and are exemplified below. Certain radiopharmaceutical agents may accumulate in tis ⁇ ues adjacent to or distant from target tis ⁇ ues. Where pos ⁇ ible, radiopharmaceutical agent ⁇ will be chosen which do not accumulate at high levels in background tissues adjacent to suspected or known lesion ⁇ of inflammation (as compared to accumulation of the agent in more distant background tis ⁇ ue ⁇ ) .
  • EXAMPLE 2 ANIMAL MODEL OF BACTERIAL INFLAMMATION
  • a frozen sample of E. coli bacteria (clinical isolate; ATCC 9339) was used to inoculate a 10 ml tryptica ⁇ e soy medium (trypticase soy broth, BBL #11768, 30 g/L water) , and the tube was incubated overnight at 37%C.
  • the agar plate ⁇ containing bacterial colonie ⁇ were ⁇ tored upside down at 4'C.
  • a ⁇ ingle colony of bacteria from the agar plate wa ⁇ u ⁇ ed to inoculate 10 ml tryptica ⁇ e soy medium, and the tube was incubated overnight at 37 * C with vigorous shaking.
  • Two ml of this overnight culture was transferred into 100 ml trypticase soy medium and the sample incubated at 37 * C with vigorous shaking until the culture reached an OD 600 of -0.8 (in about 2 hrs) .
  • the culture was centrifuged at 5500 rpm for 5 min at 4 * C in a Sorvall SS-34 rotor, the bacterial pellet resuspended in saline to give -2.5 x IO 9 bacteria/ml, and 0.1 ml of resu ⁇ pended cell ⁇ injected into the left thigh muscle of each anesthetized rat.
  • each rat de ⁇ cribed in Example 2 received an intramuscular injection of E. coli or after each rat described in Example 1 received an intramuscular injection of turpentine oil (to permit comparison of activity in a bacterial inflammation lesion ⁇ to activity in a sterile inflammation lesions) in the left rear thigh, each rat received either 125 IUdR (about 5 ⁇ Ci/rat) or gallium-67 citrate (about 10 ⁇ Ci/rat) suspended in 0.1 ml saline, by injection into the tail vein.
  • each radiopharmaceutical (measured as a function of the % injected dose/gram body weight) wa ⁇ then determined in variou ⁇ normal ti ⁇ ue ⁇ and organs, as well a ⁇ the left and right leg ⁇ , the pu ⁇ cap ⁇ ule formed within the leg and in contralateral mu ⁇ cle ti ⁇ ues (i.e., background tis ⁇ ue ⁇ unaffected by inflammation) of equivalent weight.
  • each radiophar ⁇ maceutical in various tissues of each rat (i.e., the "biodistribution" of each radiopharmaceutical)
  • samples of background tissues and organs blood, lung, liver, spleen, kidney, muscle and intestine
  • target tissue the pus capsule formed in the leg
  • contralateral muscle tis ⁇ ue background tissue adjacent to target tis ⁇ ue
  • Radioactivity in each ⁇ ample wa ⁇ mea ⁇ ured in a well-type gamma counter from LKB, Wallac Oy, Finland.
  • a well-type gamma counter from LKB, Wallac Oy, Finland.
  • aliquots of the injected doses were counted at the same time that radioactivity in each sample was determined. The results were measured as a function of the percentage of injected dose/gram (%ID/g) .
  • %ID/g percentage of injected dose/gram
  • Injected dose (ID. : 10 ⁇ Ci/rat 67 Ga;
  • a b %ID/g over contralateral muscle
  • Injected do ⁇ e 10 ⁇ Ci/rat 67 Ga; 5 ⁇ Ci/rat 125 IUdR; i.v.
  • Examples 1 and 2 received intravenous injections of either 123 IUdR (at a dose of about 1.5 mCi/rat) or gallium-67 citrate (at a dose of about 0.2 mCi/rat) .
  • rats from each group were anesthetized and imaged using a gamma camera (the General Electric STARCAM" 400 fitted with parallel hole medium collimator) .
  • Anterior images were obtained IO 6 counts/frame except for the 24 h period for 123 IUdR where a 15 min scan was carried out.
  • a 20% window was present over the 159 keV photopeaks of 67 Ga (93 keV, 184 keV, and 298 keV) .
  • Regions of interest were drawn over the inflamed areas (3x4 pixel) and over the contralateral area in each rat. Total counts in these regions were u ⁇ ed to calculate Target to Background (T/B) ratios and to calculate Figure of Merit (FOM; statistical significance) values u ⁇ ing either of the following equation ⁇ :
  • a b counts in ROl (3x4) over contralateral mu ⁇ cle.
  • Equation (1) i ⁇ derived from the Report of the National Council on Radiation Protection and Measurements, Nuclear Medicine, " Factors influencing the Choice and Use of Radionuclides in Diagnosis and Therapy” , Report No. 70, p.79 (NRCP, Bethesda, MD., 1982).
  • Equation (2) is derived from Rubin et al . , J. Nucl . Med. 30:385-389, 1989. For purposes of reference, the disclo ⁇ ure ⁇ of each of the ⁇ e publications i ⁇ incorporated herein.
  • Injected dose 0.2 mCi 67 Ga-citrate
  • Ratios (mean ⁇ SD) in Rats with sterile Inflammation Following i.v. Injection of 67 Ga-Citrate or 123 IUdR
  • Injected dose 0.2 mCi/rat 67 Ga
  • a b counts in ROl (3x4) over contralateral muscle
  • a b counts in ROl (3x4) over contralateral muscle
  • 1 3 Iodine emits 159 keV gamma photons which are ideal for external imaging.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un procédé de détection et de localisation de lésions provoquées par des inflammations bactériennes et stériles chez un patient. Ce procédé permet de détecter in vivo et de localiser l'inflammation une ou deux heures après l'administration d'un agent radiopharmaceutique au patient. Les agents radiopharmaceutiques mis en application dans le procédé sont des nucléosides et des nucléotides marqués par un radioisotope. Les radioisotopes mis en application dans les agents radiopharmaceutiques sont des émetteurs de rayons gamma (de préférence, des rayons gamma halogènes) et des émetteurs de positrons. On administre ces agents radiopharmaceutiques par voie parentérale, de préférence, dans un véhicule acceptable pharmaceutiquement.
PCT/US1996/010452 1995-06-19 1996-06-17 Procede de detection et de localisation par radioisotope d'une inflammation chez un patient Ceased WO1997000089A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/492,425 US5811073A (en) 1995-06-19 1995-06-19 Method for radioisotopic detection and localization of inflammation in a host
US08/492,425 1995-06-19

Publications (1)

Publication Number Publication Date
WO1997000089A1 true WO1997000089A1 (fr) 1997-01-03

Family

ID=23956204

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/010452 Ceased WO1997000089A1 (fr) 1995-06-19 1996-06-17 Procede de detection et de localisation par radioisotope d'une inflammation chez un patient

Country Status (2)

Country Link
US (1) US5811073A (fr)
WO (1) WO1997000089A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109080A3 (fr) * 2007-03-01 2009-04-30 Siemens Medical Solutions Marqueurs d'imagerie de la prolifération à base de nucléosides

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818227B1 (en) 1999-02-08 2004-11-16 Alza Corporation Liposome composition and method for administration of a radiosensitizer
US7238338B1 (en) 2001-06-22 2007-07-03 Triumf System and method for the large scale labeling of compounds with radiohalogens
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
WO2003059153A2 (fr) * 2002-01-15 2003-07-24 Vanderbilt University Composition et procedes d'imagerie pour une evaluation pharmacocinetique et pharmacodynamique d'un systeme d'administration therapeutique
AU2003233644A1 (en) * 2002-05-22 2003-12-12 Edward H. Abraham Labeled adenosine for use in positron emission tomography
US20080193377A1 (en) * 2004-06-28 2008-08-14 University Of Maryland, Baltimore Radiolabeled Nanohybrids Targeting Solid Tumor Neovasculature and Method of Using Same
CA2699967C (fr) * 2007-09-19 2016-11-22 The Regents Of The University Of California Sondes de tomographie par emission de positrons pour imagerie d'activation immune et cancers selectionnes
CA2967254C (fr) 2008-02-29 2019-03-26 Lantheus Medical Imaging, Inc. Agents de contraste destine aux applications comprenant l'imagerie du cancer
DK3323810T3 (da) 2010-02-08 2022-03-28 Lantheus Medical Imaging Inc Automatiseret reaktionssystem, kassette og indretning til syntese af billeddannelsesmidler
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851520A (en) * 1988-01-29 1989-07-25 President & Fellows Of Harvard College Method of making radioiodinated pyrimidine nucleoside or nucleotide
US5376356A (en) * 1989-03-14 1994-12-27 Neorx Corporation Imaging tissue sites of inflammation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211773A (en) * 1978-10-02 1980-07-08 Sloan Kettering Institute For Cancer Research 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides
US4489052A (en) * 1982-09-15 1984-12-18 Sloan-Kettering For Cancer Research Quantitative autoradiographic mapping of focal herpes simplex virus encephalitis using a radiolabeled antiviral drug
US5106837A (en) * 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
DE68925032T2 (de) * 1988-08-15 1996-04-25 Brigham & Womens Hospital Leukozyten-adhäsions-inhibitor.
US5322838A (en) * 1988-11-16 1994-06-21 Brigham & Women's Hospital Use of INHIB (the C3 β-chain) in the detection and inhibition of inflammation
US5094835A (en) * 1990-03-30 1992-03-10 The President And Fellows Of Harvard College Diagnosis of tumors with 5-(123 I)iodo-2'-deoxyuridine
US5077034A (en) * 1990-03-30 1991-12-31 The President And Fellows Of Harvard College Treatment of tumors with 5-radioiodo-2'-deoxyuridine
US5211937A (en) * 1990-07-30 1993-05-18 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
US5354751A (en) * 1992-03-03 1994-10-11 Sri International Heteroaroyl 10-deazaamino-pterine compounds and use for rheumatoid arthritis
GB9205071D0 (en) * 1992-03-09 1992-04-22 Wellcome Found Therapeutic nucleosides
US5308605A (en) * 1992-08-27 1994-05-03 The President And Fellows Of Harvard College Diagnosis of tumors with 5-radioiodo-2'-deoxyuridine
US5476855A (en) * 1993-11-02 1995-12-19 Mahmoud H. el Kouni Enzyme inhibitors, their synthesis and methods for use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851520A (en) * 1988-01-29 1989-07-25 President & Fellows Of Harvard College Method of making radioiodinated pyrimidine nucleoside or nucleotide
US5376356A (en) * 1989-03-14 1994-12-27 Neorx Corporation Imaging tissue sites of inflammation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109080A3 (fr) * 2007-03-01 2009-04-30 Siemens Medical Solutions Marqueurs d'imagerie de la prolifération à base de nucléosides
US7928210B2 (en) 2007-03-01 2011-04-19 Siemens Medical Solutions Usa, Inc. Nucleoside based proliferation imaging markers

Also Published As

Publication number Publication date
US5811073A (en) 1998-09-22

Similar Documents

Publication Publication Date Title
Volkert et al. 99mTc-propylene amine oxime (99mTc-PnAO); a potential brain radiopharmaceutical
FI82379C (fi) Radioaktivt maerkta monoklonala antikroppar samt en komposition innehaollande dessa och anvaendbar som diagnostiskt radiofarmaseutiskt medel.
Davis et al. Comparison of 225actinium chelates: tissue distribution and radiotoxicity
Anderson et al. Copper-64-labeled antibodies for PET imaging
Levchenko et al. Evaluation of 11C-colchicine for PET imaging of multiple drug resistance
US4634586A (en) Reagent and method for radioimaging leukocytes
JP6953444B2 (ja) Ｐｅｔイメージング用免疫修飾因子
Shelton et al. Assessment of regional myocardial and renal blood flow with copper-PTSM and positron emission tomography.
Oyen et al. Detecting infection and inflammation with technetium-99m-labeled stealth® liposomes
Ott et al. Treatment planning for 131I-mIBG radiotherapy of neural crest tumours using 124I-mIBG positron emission tomography
Fujita et al. Whole-body biodistribution, radiation absorbed dose, and brain SPET imaging with [123I] 5-IA-85380 in healthy human subjects
US5811073A (en) Method for radioisotopic detection and localization of inflammation in a host
EP0975373B1 (fr) Radionuclide associe a un polyphosphate nucleotidique en tant qu'agents d'imagerie de tumeurs
Goodwin et al. Chelate conjugates of monoclonal antibodies for imaging lymphoid structures in the mouse
McAfee et al. 99mTc-HM-PAO for leukocyte labeling—experimental comparison with 111In oxine in dogs
Appelbaum et al. Specific marrow ablation before marrow transplantation using an aminophosphonic acid conjugate 166Ho-EDTMP
US4430319A (en) Radioactive iodine labeled phenolic amines
Murugesan et al. Technetium-99m-cyclam AK 2123: a novel marker for tumor hypoxia
Müller-Suur et al. Renal and extrarenal handling of a new imaging compound (99m-Tc-MAG-3) in the rat
Prasanphanich et al. The effects of linking substituents on the in vivo behavior of site-directed, peptide-based, diagnostic radiopharmaceuticals
Signore et al. Biological imaging for the diagnosis of inflammatory conditions
Touya et al. The lung as a metabolic organ
US4360509A (en) Vivo radioassay process
Gobuty et al. Organ distribution of 99mTc-and 51Cr-labeled autologous peripheral blood lymphocytes in rabbits
Kubota et al. Technetium-99m-pyridoxylideneglutamate, a new agent for gallbladder imaging: comparison with 131I-rose bengal

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase